Nipro Of Japan To Begin Marketing Human iPS Cells To Drug Makers
This article was originally published in PharmAsia News
Executive SummaryJapan's Nipro says it plans to launch soon the nation's first sale of cultivated human stem cells to drug makers and research institutes. Nipro said sales should begin in June of cardiac muscle cells developed from human induced pluripotent stem cells. Similar cells from iPS cells in monkeys already are available on the market, but Nipro expects the human samples to enable assessments of drug side effects more readily, improving the speed and efficacy of clinical tests. The cells to be marketed as kits were produced by ReproCell, a Japanese biotech venture. (Click here for more - a subscription may be required
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
With a global supply chain and commercial platform, the Viatris entity to be formed by the merger of Mylan and Pfizer’s Upjohn unit wants to be the partner of choice for mid-sized products overlooked by companies focused on blockbusters.
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.